Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 37,500 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the transaction, the chief executive officer owned 37,500 shares of the company's stock, valued at approximately $6,343,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Amirali Talasaz also recently made the following trade(s):
- On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total value of $17,638,207.88.
- On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12.
Guardant Health Stock Performance
Shares of GH stock opened at $163.18 on Tuesday. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The firm has a market capitalization of $21.90 billion, a PE ratio of -46.76 and a beta of 1.60. The stock has a fifty day moving average of $154.58 and a two-hundred day moving average of $119.07.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to analyst estimates of $314.23 million. Guardant Health's revenue for the quarter was up 44.3% on a year-over-year basis. During the same period last year, the business posted ($0.44) earnings per share. Equities research analysts predict that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
GH has been the topic of a number of research analyst reports. Piper Sandler raised their price objective on shares of Guardant Health from $135.00 to $193.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. BTIG Research increased their price target on Guardant Health from $190.00 to $195.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Stephens lifted their price target on Guardant Health from $170.00 to $195.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Royal Bank Of Canada boosted their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Finally, Bank of America upped their price objective on Guardant Health from $135.00 to $190.00 and gave the company a "buy" rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $183.78.
Get Our Latest Stock Analysis on Guardant Health
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. ABS Investment Management LLC acquired a new stake in shares of Guardant Health during the 2nd quarter valued at $345,069,000. TrinityBridge Ltd bought a new stake in shares of Guardant Health during the 2nd quarter worth $45,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health in the 4th quarter worth $35,000. Parallel Advisors LLC grew its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock worth $36,000 after acquiring an additional 219 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Guardant Health during the second quarter worth $59,000. Institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
